America’s biotech race with China must be won at home

Former U.S. officials Gary Locke and Patrick McHenry argue that America must build up domestic biotech capabilities rather than merely containing China. Beijing aims by 2030 to produce 25% of the world's first-in-class drugs—currently produced by the U.S. at seven times that rate—and grow its innovative industry by 20% annually.